02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
01:54 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Catabasis raises $20 million follow-on

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) raised $20 million on Feb. 6 in a follow-on on through the sale of four million units at $5. The price is a 17% discount to the endocrine and metabolic company's...
19:27 , Oct 9, 2018 |  BC Extra  |  Company News

Management tracks: Pfizer unveils Bourla’s team

Incoming Pfizer Inc. (NYSE:PFE) CEO Albert Bourla’s executive team will include a chief digital and technology officer and see Global President of Worldwide R&D and Medical Mikael Dolsten add the title of CMO. The new...
17:33 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Catabasis reports 60-week data for edasalonexent in DMD

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the U.S. Phase I/II MoveDMD trial in steroid-naïve Duchenne muscular...
22:55 , Feb 13, 2018 |  BC Extra  |  Clinical News

Catabasis gains on 60-week DMD data

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) was up $0.31 (25%) to $1.56 on Tuesday after reporting that edasalonexent (CAT-1004) preserved muscle function and slowed disease progression through 60 weeks of treatment in an open-label extension of the...
19:11 , Oct 13, 2017 |  BioCentury  |  Regulation

Seeking surrogates

Thanks to flaws in PTC Therapeutics Inc. ’s trials, the recent FDA advisory committee meeting to discuss Translarna ataluren did nothing to clarify what level of dystrophin expression would be necessary to support an accelerated...
20:46 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Ataxia Cell culture studies suggest inhibiting NF-κB could help treat spinocerebellar ataxia type 17 (SCA17), which is caused by CAG/CAA repeat expansions in the TBP gene. In co-cultures of primary neurons and astrocytes from...
19:09 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Catabasis' DMD candidate slows disease progression in Phase I/II

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the open-label extension of the Phase I/II MoveDMD trial showing that edasalonexent (CAT-1004) slowed disease progression in boys ages 4-7 with Duchenne muscular dystrophy (DMD). The company plans...
08:57 , Oct 4, 2017 |  BC Extra  |  Clinical News

Catabasis reports DMD candidate slowed disease progression

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $0.20 to $3.03 on Wednesday after it said results from the open-label extension of the Phase II MoveDMD trial showed edasalonexent (CAT-1004) slowed disease progression in boys aged 4-7 with...
19:56 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Lightstone closes $250M fund

On Sept. 20, Lightstone Ventures (Menlo Park, Calif.) closed Lightstone Ventures II at $250 million. Lightstone said the fund will invest $15-$20 million in each of about 15 early stage biotech and medical device companies....